Skip to main content

Table 3 Initial anaphylactic reaction to a bee field sting compared between patients experiencing an adverse reaction (AR) to immunotherapy and those without complications (NC)

From: Anaphylactic reactions in the build-up phase of rush immunotherapy for bee venom allergy in pediatric patients: a single-center experience

  All patients AR NC  
No. of patients 19 3 16 P
Median grade of anaphylactic reaction to initial field sting 2 2 2 n.s
No. (%) of patients with dermal symptoms 19 (100.0) 3 (100.0) 16 (100.0) n.s
(95% CI) (100 to 100) (100 to 100) (100 to 100)  
No. (%) of patients with gastrointestinal symptoms 6 (31.6) 1 (33.3) 5 (31.3) n.s
(95% CI) (12.6 to 56.6) (0.8 to 90.6) (11.0 to 58.7)  
No. (%) of patients with respiratory symptoms 13 (68.4) 2 (66.7) 11 (68.8) n.s
(95% CI) (43.5 to 87.4) (9.4 to 99.2) (41.3 to 89.0)  
No. (%) of patients with cardiovascular symptoms 10 (52.6) 1 (33.3) 9 (56.3) n.s
(95% CI) (28.9 to 75.6) (0.8 to 90.6) (29.9 to 80.3)  
  1. AR patients experiencing an adverse reaction to immunotherapy, NC patients undergoing immunotherapy without complications, CI confidence interval, No. number